Utah Founder 100 Honorees Named
Venture Capital Podcast has released their Founder 100 honoree list for Utah. It is a crowd-nominated, peer-voted list of the state's top founders in terms of their attractiveness to investors. The honorees and a large group of investors will meet this evening in a...
Utah executives’ top 10 business apps
By Brittny Goodsell -- Utah Business Magazine David Bearss, CEO of Halia Therapeutics, says his company uses Carta to manage multiple things. “Biotech companies are always in need of large capital raises to support the expenses from clinical development of new...
Halia: Leveraging RAB10 as a new lens on the NLRP3 inflammasome
BioCentury Guided by human variation in the GTPase RAB10, Utah-based company seeks to disrupt inflammasome assemblyBY RICHARD GUY, BIOPHARMA ANALYSTMay 23, 2024 Halia has a new take on drugging the NLRP3 inflammasome that centers on exploiting RAB10 biology to control...
AI Versus Alzheimer’s
By Heather Bergerson -- Utah Business Magazine Utah-based companies Halia Therapeutics and Canary Speech are collaborating to revolutionize how Alzheimer's disease can be monitored and treated. https://bit.ly/3z2AhkH
Dr. David Bearss Joins Conversations Life Science Leaders Aren’t Having Podcast
Beyond Employee Engagement: Unpacking Performance in Life Sciences Leadership - Executive Roundtable April 1, 2024 In this insightful episode of Conversations Life Science Leaders Aren't Having, Jeff Harmon hosts an invaluable Life Science Executive Roundtable. The...
Fighting Inflammation and Alzheimer’s – Dr. David Bearss on BioTech Nation podcast
March 20, 2024/28:57/E24012 In this episode of BioTech Nation, Dr. David Bearss, President, and CEO of Halia Therapeutics, discusses inflammation and its reduction over a lifetime and in response to various incidents. He unveils the inflammasome, a recently discovered...
Clinical Trials Arena: Halia Therapeutics begins trial of HT-6184 for pain management
The study will enroll up to 80 adults who are undergoing the surgical removal of two or more molar teeth for inflammatory and pain management. February 16, 2024 US-based biopharmaceutical company Halia Therapeutics has begun a Phase II clinical trial to...
BioWorld: Halia to use Canary Speech’s AI vocal biomarker platform to inform development of HT-4253 for Alzheimer’s
Halia Therapeutics Inc. and Canary Speech Inc. have established a collaboration in Alzheimer’s disease. This collaboration leverages Canary Speech’s artificial intelligence (AI) vocal biomarker platform, which utilizes advanced AI algorithms to analyze subtle changes...
BioWorld – Halia closes a $30M series C to develop inflammasome inhibitors
Lee LandenbergerJanuary 31, 2024 Halia Therapeutics Inc. has, its CEO confidently asserts, taken an atypical road to building its infrastructure and financing. The Lehi, Utah-based company just completed a $30 million series C financing to further develop its lead...
WSJ: The Future of Biotech Venture Capital – Read what Dr. David Bearss has to say
Biotech Acquisitions Heat Up, Giving Venture Capitalists Hope for 2024 'Investors and entrepreneurs also are wrestling with questions such as the impact of the 2022 Inflation Reduction Act, which enabled Medicare to negotiate prices of certain medications, said...
Longevity.Technology – Waging War on Chronic Inflammation
January 11th, 2024 Author: Danny Sullivan Dr. David Bearss was featured in Longevity.Technology discussing Halia Therapeutics moving into multiple Phase 2 trials for chronic inflammation and whether the company may have created a ‘longevity drug.’ Fresh from...
Jeff Burton – Halia Therapeutics CFO participates in BioSpace Roundtable
Alternative Funding Strategies to Discuss at JPM https://www.youtube.com/watch?v=c3PAvs5gwFE The last year has demonstrated that a sound financing strategy and compelling company narrative are essential to securing funding – it’s become more important than ever that...
Halia Therapeutics CEO David Bearss featured on Bioworld Podcast
One aspect of 2023 our group of executives completely agreed on: the past year was tough financially. And they all foresee a more vibrant year ahead for the market. Giving all of them hope were technological breakthroughs such as artificial intelligence, game changing...
Halia Therapeutics to test HT-6184 in MDS patients for first time
The Phase II trial of HT-6184 will enroll around 50 patients with MDS who are or are on the borderline of being transfusion-dependent. Halia Therapeutics is looking to start a Phase II trial of its pipeline candidate HT-6184 in myelodysplastic syndrome (MDS) early...
Utah Business: How David J. Bearss co-founded Halia Therapeutics
Starting a company is interesting. I’m a scientist by training and have often considered myself the world’s most reluctant entrepreneur. Halia Therapeutics is the sixth company I’ve started, but most of the time, I still think of myself as the guy who used...
Halia Therapeutics Announces Positive Phase 1 Clinical Trial Results for HT-6184 at the 5th Inflammasome Therapeutics Summit
LEHI, Utah, Nov. 29, 2023 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced positive results following the successful...
David Bearss is featured in Biosphere Magazine
David Bearss’ passion for drug discovery has guided his noteworthy career as a dynamic leader who integrates scientific and business interests to deliver new medicines to patients. That passion is still evident today as he gives back to the industry he loves, making a difference with bold initiatives to improve health and change the face of Utah’s life sciences ecosystem.
Halia’s new lab is featured in the Provo Daily Herald
Halia Therapeutics has a new lab in Lehi and believes it is on the forefront of research to target chronic inflammation to treat neurodegeneration and inflammatory diseases.
Halia Therapeutics Grand Opening Reported by FOX 13 KSTU August 23, 2023
Thanks to Salt Lake City’s FOX 13 News for attending and reporting on Halia Therapeutics’ grand opening. This report aired August 23, 2013.
BioTuesdays.com – Halia targeting chronic inflammation to keep people healthier, living longer
Closely-held Halia Therapeutics is developing a broad pipeline of novel therapies that are essential mediators of immune cell signaling with the potential to improve the lives of patients with inflammatory disorders and neurological diseases.